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Abstract
Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation
(allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular
monitoring. Using polymerase chain reaction (PCR) for immunoglobulin gene rearrangements it
was possible to generate a clone-specific molecular marker in 48 of 70 patients. Of these 48
patients, 16 (33%) attained durable PCR-negativity after transplantation, whereas 13 (27%)
remained persistently PCR-positive and 19 (40%) showed a mixed pattern. The cumulative risk of
relapse at 5 years was 0% for PCR-negative patients, 33% for PCR-mixed patients, and 100% for
PCR-positive patients. Within the group studied it was not possible to identify any clinical feature
predictive of durable PCR-negativity. We believe that these findings could prompt the design of
prospective studies to evaluate if the treatment of molecular disease can extend remission
duration and survival.
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Introduction
Autologous stem cell transplantation is considered the standard treatment for patients younger
than 65 years with multiple myeloma (MM).1  While this approach produces complete or near
complete remission in about 50% of patients, all patients will eventually relapse and the median
duration of response is only 42 months.2  Conversely, allogeneic stem cell transplantation (allo-
SCT) is associated with a significantly lower risk of relapse and can result in long-term disease-
free survival.3-6  The reduced relapse risk after allo-SCT is probably due to the unique capacity of
donor lymphocytes to recognize and kill recipient plasma cells. Several reports have supported the
existence of this “graft-versus-myeloma (GVM) e ect” in the allogeneic setting. However, the
potential benefit of allo-SCT is o set by the high transplant-related mortality, and therefore there is
currently widespread interest in the use of novel strategies using nonmyeloablative conditioning.7-
13  Both myeloablative and nonmyeloablative programs frequently include some additional
immunotherapeutic maneuvers, such as the early discontinuation of immunosuppression or the
use of donor lymphocyte infusions, in order to potentiate the GVM e ect.14  The preemptive
identification of patients at high risk of relapse could allow the most e ective use of
immunotherapeutic intervention with the aim of eradicating residual disease and preventing overt
hematologic relapse. There are a few reports of the use of molecular evaluation of minimal-residual
disease (MRD) in patients with myeloma, but its role in clinical management is still unknown.15,16 
To address the issue of the potential prognostic value of molecular monitoring we have carried out
a retrospective, multicentric study on a large cohort of patients who were in complete clinical
remission (CCR) after allo-SCT.
Study design
Patients and response definitions
Seventy myeloma patients in CCR after myeloablative allo-SCT from a matched sibling donor were
selected for the study. Patients underwent transplantation at 9 EBMT centers: Bologna, Genova,
Milano, Palermo, Torino (Italy), London, Nottingham (United Kingdom), Utrecht (the Netherlands),
and Huddinge (Sweden). Approval was obtained from the Istituto Nazionale dei Tumori review
board for these studies. Patient informed consent was obtained before transplantation according
to the Declaration of Helsinki. Patient characteristics are summarized in Table 1. Of the 70 patients,
50 underwent transplantation at diagnosis after initial cytoreduction and 20 later in the course of
the disease.
Table 1.
Patient characteristics according to molecular status
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 PCR-negative
 
PCR mix
 
PCR-positive
 
Number of cases  16  19  13  
Age, y (range)  44 (36-54)  43 (30-53)  43 (29-59)  
Sex, male (%)  7 (43)  10 (53)  8 (61)  
Graft source (%)     
    BM  1 (6)  4 (21)  5 (38)  
    PBSC  10 (62)  9 (47)  3 (24)  
    TCD-BM  5 (32)  6 (32)  5 (38)  
Chemosensitive disease (%)  10 (62)  14 (74)  10 (77)  
TBI-based regimen (%)  8 (50)  11 (58)  11 (84)  
aGVHD (%)     
    Grades 0-I  11 (69)  10 (53)  8 (62)  
    Grades II-IV  5 (21)  9 (47)  5 (38)  
cGVHD* (%)     
    None  4 (29)  3 (19)  5 (38)  
    Limited  2 (14)  10 (62)  4 (31)  
    Extensive  8 (57)  3 (19)  4 (31)  
Median follow up, mo (range)  36 (6-120)  46 (4-113)  23 (6-47)  
Median interval between PCR determinations, mo (range)  6 (3-29)  8 (3-46)  6 (3-34)  
3-year cumulative relapse risk, % (95% confidence interval)  0  14 (0-32)  61 (21-100)  
5-year cumulative relapse risk, % (95% confidence interval)  0  33 (5-60)  100  
Last disease status (%)     
    CCR  15 (94)  12 (63)  7 (54)  
    Relapse
 
1 (6)
 
7 (27)
 
6 (46)
 
BM indicates bone marrow; PBSC, peripheral blood stem cells; TCD-BM, T-cell—depleted bone marrow; TBI, total body
irradiation; aGVHD, acute graft-versus-host disease; and cGVHD, chronic GVHD.
* Not all patients were evaluable for chronic GVHD.
Disease response was evaluated according to previously published guidelines.17  Molecular
remission (MR) was strictly defined by the absence of any polymerase chain reaction (PCR)–
positive tests. Patients were divided in 3 groups according to their molecular status: persistently
PCR-negative (NEG), persistently PCR-positive (POS), and PCR-mixed patterns (MIX).
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Molecular analysis
Bone marrow (BM) samples were collected during standard diagnostic procedures before
transplantation and at various time points after transplantation. Pretransplantation samples from
70 patients were collected, and in 48 of these a molecular marker could be generated. In 12
patients, the pretransplantation sample was a fragment of a para in-embedded trephine biopsy,
and it was not possible to obtain a molecular marker in any of these cases because of the poor
quality of extracted DNA. In a further 10 cases, material from BM aspirates was available but a
marker could not be successfully generated. Patient-specific molecular markers were generated
from immunoglobulin heavy-chain genes, as previously described.15  After the identification of the
sequence of the rearranged variable region, patient-specific primers were designed and used for
PCR detection of minimal-residual disease. The optimal sensitivity attainable with this PCR
strategy was 10–6 (ie, the ability to detect 1 tumor cell in 106 normal BM cells).18 
Statistical analysis
The cumulative risk of relapse was assessed according to the approach described by Marubini and
Valsecchi.19  Univariate analysis to determine the possible relation of clinical features and
molecular outcome was conducted using the Fisher exact test. All P values are 2-sided.
Results and discussion
In 48 of 70 patients, a clone-specific molecular marker was obtained, and these patients were
considered informative for the study. Molecular follow-up after transplantation showed that 35
(73%) of these 48 patients had at least one PCR-negative BM sample after transplantation, of
whom 16 (33%) remained persistently negative. In the remaining 13 patients, all samples were
PCR-positive. The patients could therefore be classified into 3 groups according to their results on
molecular follow-up: (a) persistently PCR-negative (NEG), 16 cases (33%); (b) persistently PCR-
positive (POS), 13 cases (27%); and (c) PCR-mixed results (MIX), 19 cases (40%). The relapse risk
for POS patients was significantly higher than that of both NEG and MIX patients (POS vs NEG, P
= .0001; POS vs MIX, P = .002) (Figure 1A), while the NEG pattern was associated with a more
favorable cumulative relapse risk than the MIX pattern (P = .03). The cumulative risk of relapse at 5
years for NEG, MIX, and POS patients was 0%, 33%, and 100%, respectively (Table 1).
Figure 1.
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Molecular monitoring of residual myeloma cells after allogeneic stem cell transplantation.
(A) Cumulative relapse risk according to molecular status. ○ represents PCR-negative patients;
×, PCR-mixed patients; and •, PCR-positive patients. (B) Molecular follow-up. Unique patient
numbers are on the left. • indicates PCR-positive; ○, PCR-negative; R, relapse; and ✠, death.
The attainment of persistent PCR-negativity has a favorable impact, but it is not synonymous of
cure, since we observed a patient relapsing after 9 years of molecular remission (Figure 1B). The
escape from the immunologic control of a residual myeloma clone can perhaps explain the
occurrence of very late relapses.20  It is of interest that the patients with a MIX pattern have a
better outcome than those who are persistently PCR-positive, supporting the hypothesis of an
ongoing control of the residual tumor by the donor immunity. Although variable patterns of results
were seen within the MIX category, it appears that there are 2 main groups: those patients who are
initially positive and then become negative, and those who are negative but then revert to positive.
Usually patients switching from negative to positive experienced clinical relapse within a relatively
short period of time (Figure 1B). Correlations with clinical parameters were di icult because
patients were retrospectively selected for their CCR status. Data were not available for some well-
established prognostic factors such as β2 microglobulin, C-reactive protein, and cytogenetic
abnormalities. However, we were not able to identify a statistically significant correlation between
molecular outcome and any known clinical feature. There was no association between age, sex,
disease status at transplantation, graft source, acute graft-versus-host disease (GVHD), or type of
conditioning and molecular outcome, possibly as a consequence of the limited number of patients
in each category. However, a trend in favor of peripheral blood stem cell (PBSC) transplantation
was observed in persistently negative patients (NEG vs MIX, P = .06; NEG vs POS, P = .06) (Table
1). Likewise, we observed a weak association between the incidence of chronic GVHD and
molecular remission (P = .16) (Table 1). Both data points seem to support the observation that
chronic GVHD is more frequent after peripheral blood stem cell (PBSC) transplantation, and this
finding has been correlated with a more e ective control of the disease.21,22  Nevertheless, the
correlation of molecular remission and PBSC use must be interpreted with great caution and
should be tested on a larger group of cases.
Recent observations support the use of quantitative molecular methods, such as real-time PCR, to
assess changes in the level of MRD in patients with myeloma.23,24  With quantitative monitoring it
would be possible to determine whether tumor burden is lower in patients with the MIX pattern
than in those who are persistently PCR-positive. Within the MIX groups it might also be possible
17/10/2019 Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myel…
https://ashpublications.org/blood/article/102/5/1927/17531/Molecular-remission-after-myeloablative-allogeneic 7/13
Skip to Main Content
identify a threshold value able to distinguish patients with a favorable GVM/residual disease
balance who will subsequently become PCR-negative from those with a more immune-resistant
disease who are destined to relapse.
We believe that these data could prompt the design of prospective studies to evaluate if the
treatment of molecular disease can o er a low-risk opportunity to extend the duration of remission
and survival.
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